Artificial Intelligence and Machine Learning Expert Dr. Randal S. Olson Joins GWG Holdings’ Insurtech Subsidiary Life Epige...
January 11 2018 - 4:05PM
Life Epigenetics, the insurtech subsidiary of GWG Holdings,
Inc. (Nasdaq:GWGH), announced that Dr. Randal S. Olson has
joined the firm as its Lead Data Scientist. Dr. Olson will
bring machine learning, artificial intelligence and advanced data
science to the company’s epigenetic technology that promises to be
transformational to life insurance underwriting.
Dr. Olson joins Life Epigenetics from the University of
Pennsylvania where he was the Senior Data Scientist at the
Computational Genetics Laboratory. Working with Professor
Jason H. Moore, the renowned translational bioinformatics
scientist, biomedical informatician, and human geneticist, Dr.
Olson invented and developed the award-winning Automated Machine
Learning (AML) tool TPOT (https://rhiever.github.io/tpot/) which is
one of the most widely used open-source AML tools in the world.
In his role at Life Epigenetics, Dr. Olson will lead the
company’s application of predictive epigenetic biomarkers to life
insurance underwriting through the use of artificial intelligence
and machine learning. The company’s epigenetic analysis currently
captures methylation levels at over 866,561 sites along the human
genome. Methylation levels at these sites vary based on age,
lifestyle, exposure to toxins, and various other environmental
factors. Using machine learning and artificial intelligence, Life
Epigenetics will be able to apply advanced automated machine
learning to life insurance underwriting.
“Randy will play an important role in applying machine learning
and artificial intelligence to the vast amounts information we are
now able to see about our human biology through epigenetic
analysis,” said Life Epigenetics’ CEO Jon Sabes. “Attracting a
professional like Dr. Olson to Life Epigenetics is an exciting
milestone for the company.”
"We are thrilled to have Dr. Olson join our scientific team,”
said Life Epigenetics’ Chief Scientist Dr. Brian Chen. “His
expertise in data science will enhance our ability to fully
maximize our cutting-edge technologies in the biological
sciences."
Life Epigenetics holds the exclusive license for
lifespan-predictive technology developed at the University of
California, Los Angeles (UCLA) for the life insurance industry.
Since February 2017 the company has been collecting and analyzing
data from life insurance policyholders and has been discussing its
work with major life insurance and reinsurance companies that have
expressed interest in learning more about how epigenetic technology
can add value to their businesses. In October, it announced
pilot programs with two life insurance companies to test its
epigenetic-based M-Panel technology.
Dr. Olson received a Ph.D. in computer science and ecology,
evolutionary biology and behavior from Michigan State
University.
About Life Epigenetics
Life Epigenetics is the insurtech subsidiary of GWG Holdings,
Inc. (Nasdaq:GWGH) that is dedicated to creating transformational
technology for the life insurance industry based on advanced
epigenetic science. The company’s “DNA methylation-based predictor
of mortality technology,” exclusively licensed from the University
of California, Los Angeles (UCLA), provides unprecedented new
insight into longevity using epigenetics.
For more information about Life Epigenetics, Inc.,
visit www.lifeegx.com
About GWG Holdings, Inc.
GWG Holdings, Inc. (Nasdaq: GWGH), the parent company of GWG
Life and Life Epigenetics, is a financial services company
committed to transforming the life insurance industry through
disruptive and innovative products and services. GWG Life is
developing a suite of new longevity-based products for consumers
and financial advisors under the LifeCare Xchange (LCX) platform
that provides consumers owning life insurance the opportunity to
exchange their policies for products that can be used to pay for
long-term care and other retirement financial needs. Life
Epigenetics seeks to further transform the industry by applying
proprietary M-Panel epigenetic technology to disrupt traditional
life insurance underwriting practices. Since 2006, GWG Life has
provided seniors over $457 million in exchange value for their life
insurance and, as of Sept. 30, 2017, owned a portfolio of over
$1.62 billion in face value of policy benefits.
For more information about GWG Holdings, Inc.
email info@gwglife.com or visit www.gwgh.com.
Dan Callahan
Director of Communication
Life Epigenetics
(612) 746-1935
dcallahan@gwglife.com
GWG (NASDAQ:GWGH)
Historical Stock Chart
From Aug 2024 to Sep 2024
GWG (NASDAQ:GWGH)
Historical Stock Chart
From Sep 2023 to Sep 2024